Colchicine for Reduction of Periprocedural Myocardial Injury in Percutaneous Coronary Intervention

NCT05745818 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-02-27

No results posted yet for this study

Summary

Study of role of colchicine in reducing periprocedural myocardial injury in patients prepared for elective PCI and its role in reduction of MACEs.

Conditions

  • Periprocedural Myocardial Infarction
  • Periprocedural Myocardial Injury

Interventions

DRUG

Colchicine Pill

oral pills

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-03-01
Completion
2025-03-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05745818 on ClinicalTrials.gov